21.02.2013 - Global acreage of biotech crops have increased by 6% last year. Europe contributes only 0.075%.
Brussels/Manila - Genetically modified (GM) soybeans, maize, cotton and rapeseed were planted on 170.3 million hectares last year, according to figures from the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). However, the adoption of biotech crops has become slower. After double digit growth rates three years ago, this year the cultivation area increased only by 6 percent or 10.3 million hectares compared to 2011.
However, Europe remains a minor player in the growing market for GMOs due to public hostility to GMOs. The EU countries grew 129,071 hectares of Bt maize, about 14,000 hectares more than in 2011. Spain remained the leading EU country for GMO acreage with 116,306 hectares in 2012. Poland discontinued the planting of biotech maize. The US (69.5m ha, +0.7%), Brazil (36.6m ha, +20,8%), Argentina (23.9m ha, +0,8%), Canada (11.6m ha, +11,5), and India (10.6m ha, +1,8%) were the leading GMO producers. Global Adoption of GM soybeans (+8%), cotton (+7%), maize (+4%), and rapeseed (+5%) increased as compared to 2011.
"There is one principal and overwhelming reason that underpins the trust and confidence of farmers in biotechnology: biotech crops deliver substantial, and sustainable, socio-economic and environmental benefits," stressed ISAAA chief Clive James. In fact, German BASF and Monsanto both filed for US approval of the first drought-tolerant crop last year. However, the US Department of Agriculture recently delayed the approval of new herbicide-tolerant GMOs because weeds are becoming more and more resistant to the herbicide Glyphosate, which is marketed together with Glyphosate-tolerant GMOs since 1996.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more